These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18806189)

  • 1. Decision analysis for resource allocation in health care.
    Griffin S; Claxton K; Sculpher M
    J Health Serv Res Policy; 2008 Oct; 13 Suppl 3():23-30. PubMed ID: 18806189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.
    Hoomans T; Fenwick EA; Palmer S; Claxton K
    Value Health; 2009; 12(2):315-24. PubMed ID: 18657098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
    Barbieri M; Hawkins N; Sculpher M
    Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom.
    Kanavos P; Trueman P; Bosilevac A
    Int J Technol Assess Health Care; 2000; 16(4):1179-92. PubMed ID: 11155837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
    Fenwick E; Steuten L; Knies S; Ghabri S; Basu A; Murray JF; Koffijberg HE; Strong M; Sanders Schmidler GD; Rothery C
    Value Health; 2020 Feb; 23(2):139-150. PubMed ID: 32113617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
    Sculpher M; Claxton K
    Value Health; 2005; 8(4):433-46. PubMed ID: 16091019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
    Rothery C; Strong M; Koffijberg HE; Basu A; Ghabri S; Knies S; Murray JF; Sanders Schmidler GD; Steuten L; Fenwick E
    Value Health; 2020 Mar; 23(3):277-286. PubMed ID: 32197720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
    Wallerstedt SM; Henriksson M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules.
    O'Brien BJ; Sculpher MJ
    Med Care; 2000 May; 38(5):460-8. PubMed ID: 10800973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring structural uncertainty in model-based economic evaluations.
    Afzali HH; Karnon J
    Pharmacoeconomics; 2015 May; 33(5):435-43. PubMed ID: 25601288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model.
    Tappenden P; Chilcott J; Brennan A; Squires H; Glynne-Jones R; Tappenden J
    Value Health; 2013 Jun; 16(4):542-53. PubMed ID: 23796288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presentation of economic evaluation results.
    Chaikledkaew U; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S66-73. PubMed ID: 19253489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.
    Franklin M; Lomas J; Richardson G
    Pharmacoeconomics; 2020 Jul; 38(7):665-681. PubMed ID: 32291596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty.
    Sendi P; Al MJ
    Soc Sci Med; 2003 Sep; 57(6):969-74. PubMed ID: 12878098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationing health care: from needs to markets? The politics of destruction: rationing in the UK health care market.
    Pollock AM
    Health Care Anal; 1995 Nov; 3(4):299-308; discussion 309-14. PubMed ID: 10156208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision Making for Healthcare Resource Allocation: Joint v. Separate Decisions on Interacting Interventions.
    Dakin H; Gray A
    Med Decis Making; 2018 May; 38(4):476-486. PubMed ID: 29683792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.
    Tappenden P; Chilcott J; Brennan A; Squires H; Stevenson M
    Value Health; 2012 Dec; 15(8):1127-36. PubMed ID: 23244816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.